AVXL IS ridiculously undervalued. There is no serious shorter or analyst predicting that A273 will not be able to even SOC one of the aimed diseases. If A273 will even succeed in ONE of the many upcoming last phase trials its worth a SP of at least $ 25-30 given present issued share count. And easy within reach within next 9 to 12 months. There are biotechs out there who would dream of the trial position Anavex has and are valued at billions.
The SP beating of the last 6 months would be appropriate for a biotech suffering from a huge trial technical set back. Anavex presented us in Nov that it delivering on its drug promises and gets a beating because of a few months delay. ??
Market Data 
Markets 
AI
